Reacción #366759

ord-cf48698105984d01ad3168b3212158d6

Condiciones de reacción

Condiciones detalladas
See reaction.notes.procedure_details.

Tratamiento posterior

  1. 1
    Otro(prepared
  2. 2
    Otrothe product was separated by elution with methylene chloride/acetonitrile/methanol (60/35/35)
  3. 3
    OtroThe purified solid product was triturated with ether
  4. 4
    Filtracióncollected by filtration
  5. 5
    workup.DISSOLUTIONThe solid was dissolved in methylene chloride/methanol
  6. 6
    workup.ADDITIONa solution of 3M ethereal hydrogen chloride (1 ml) was added
  7. 7
    FiltraciónThe solid was collected by filtration
  8. 8
    Lavadowashed with ether
  9. 9
    Otrodried under vacuum

Procedimiento

Diethyl azodicarboxylate (261 mg, 1.5 mmol) was added dropwise to a suspension of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (160 mg, 0.5 mmol), (prepared as described for the starting material in Example 24), triphenylphosphine (393 mg, 1.5 mmol) and 2-(N-(2,6-dimethyl-4-pyridyl)-N-methylamino)ethanol (125 mg, 0.7 mmol) in methylene chloride (5 ml) and the mixture stirred for 2 hours at ambient temperature. Methanol (10 drops) was added and the mixture was poured on to a column of neutral aluminium oxide and the product was separated by elution with methylene chloride/acetonitrile/methanol (60/35/35). The purified solid product was triturated with ether and collected by filtration. The solid was dissolved in methylene chloride/methanol and a solution of 3M ethereal hydrogen chloride (1 ml) was added. The solid was collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-7-(2-(N-(2,6-dimethyl-4-pyridyl)-N-methylamino)ethoxy)-6-methoxyquinazoline (170 mg, 61%).

Fuente

DOI: 10.6084/m9.figshare.5104873.v1Patente: US06362336B1uspto-grants-2002_03